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The Quest for an
AIDS Vaccine
Robert T Schooley, M.D.
More thanfifty thousand cases ofAIDS have been reported in the United States since the
disease wasfirst described in 1981. Many times this number ofpeople are infected with
human immunodeficiency virus (HIV), which has been identified as the agent responsible
for the illness. The seriousness ofthe disease, coupled with the relatively rapid spread of
HIV, hasfueled the effortfor development ofan effective vaccine.
Much is now known about the life cycle ofthe virus, and about its structural compo-
nents. This information, and information about methods oftransmission ofthe virus, form
the basisfor a rational vaccine developmentprogram. A successfulprogram depends both
on technological advances and on the political will to create a climate in which interpret-
able vaccine trials can be undertaken. This review willfocus on some ofthe impediments
to rapid development and licensure ofan AIDS vaccine.
Since the initial description ofAIDS in 1981 , and the initial definition of the human
immunodeficiency virus (HIV) as the etiologic agent for the syndrome, much prog-
ress has been made in understanding the cell and molecular biology of HIV, and in defin-
ing the components of the immune response to the agent. In parallel with the growth in
basic understanding of HIV, the agent has spread rapidly in the United States and world-
wide, primarily through sexual, blood-borne, and perinatal exposure. It has been esti-
mated that between 1 million and 3 million residents of the United States are currently
infected with HIV, and that at least as many individuals are infected in other parts of the
world. This relatively rapid spread of HIV, despite educational efforts aimed at interdic-
ting spread of the agent, underscores the urgent need for development of an effective
AIDS vaccine. This article will outline current prospects for development of an AIDS
vaccine, and will delineate the steps required for the proof of efficacy in clinical trials.
Initial Infection and Spread ofHIV
HIV gains access to the body either transmucosally (across mucous membranes) in sexual
Dr. Robert T. Schooley is associate professor ofmedicine at the Harvard Medical School and is a member ofthe
Infectious Disease Unit at the Massachusetts General Hospital.
135
New England Journal ofPublic Policy
transmission, or directly into the bloodstream or soft tissues with blood-borne (needle
stick or transfusion) exposures (figure 1). In that the virus lives primarily within cells,
it is not clear whether spread involves free virus or virus transmitted within cells. Once
within the new host, the virus enters susceptible cells. The genetic material of the virus is
acted upon by an enzyme known as reverse transcriptase, which is brought into the cell by
the virus. The genetic material of the virus is then integrated into the host cell DNA. The
virus may remain latent and be transmitted to any progeny of the infected host cell, or it
may begin to reproduce and be transmitted to previously uninfected, susceptible cells.
Although it is possible that a vaccine might slow secondary transmission of virus to unin-
fected cells, the primary goal in most vaccination programs involves prevention of estab-
lishment of the initial infection.
In the case of HIV, this initial interception of virus by the immune response might be
complicated by the ability of the virus to spread directly from infected to uninfected lymph-
ocytes through cell-to-cell spread, and by the possibility that the initial infection of host
cells might occur at mucosal surfaces such as vaginal and rectal linings. Initial infection at
these sites might significantly limit the effectiveness of immune response induced by
traditional vaccines.
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The figure describes interaction between HIV and the infected individual. The virus gains entry to the
body through mucous membranes with sexual exposure, or more directly through blood-borne
exposure. After entry, the virus infects certain cells of the immune system and the brain. The immune
response that is evoked by the virus is multifaceted and probably slows the rate at which the virus
causes illness. Greater knowledge about the characteristics of this immune response will be useful in
vaccine development.
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Host Immune Response to HIV
Once the virus is within an individual, replication of HIV proceeds at a rate that may be
dependent on a number of factors, including the state of activation of host cells; the HIV-
specific host immune response; and, possibly, virus-specific strain differences. As the
initial cycles of viral replication proceed, a vigorous antibody and cellular immune re-
sponse to the virus is developed. The antibody response to HIV is directed to a number of
viral components. These antibodies are useful diagnostically in the identification of HIV-
infected individuals, but, more important, they provide insight into the components of the
virus recognized by the host as being foreign.
Antibody activity can be measured in functional assays that measure biologic effects of
the antibodies. The functional assay that has been most extensively studied for the purpose
of vaccine strategy is the neutralization assay. In this assay, dilutions of sera to be tested
are mixed with a known amount of virus. After exposure of the virus to serum for a de-
fined length of time, the ability of the serum-exposed virus to infect susceptible cells is
tested. If protection of susceptible cells by a given dilution of serum is demonstrated, the
serum is said to contain neutralizing activity at that dilution. Neutralizing activity appears
within the serum of most HIV-infected individuals within the first several months follow-
ing infection. These assays are useful in planning vaccine approaches because they permit
investigators to determine which parts of the virus are able to elicit antibodies that cripple
its ability to infect host cells. In the case of HIV-1 (the most common AIDS virus type in
the United States), this neutralizing activity is most easily demonstrated in antibodies that
react with the envelope (surface) of the virus.
Although one can demonstrate neutralizing activity specific for the envelope of HIV-1
,
such knowledge is far from sufficient for providing an effective vaccine. As noted above,
such antibodies must be present at the site of initial infection, such as the rectal or vaginal
mucosa. Furthermore, HIV possesses an envelope that varies significantly from strain to
strain. In addition to the two currently known types of HIV, within each type there are
many, many strains. Thus, an antibody that is able to neutralize one strain of virus may be
less able to neutralize other strains of virus, or may be incapable of doing so. In addition,
with the description of a second type of HIV, now termed HIV-2, which was initially iso-
lated in west Africa, vaccine development is faced with the need to deal with at least two
types ofHIV
Although the antibody response to HIV is the aspect of the immune response which has
been most intensively studied, it is clear that neutralizing antibodies represent only one
component of a multifaceted response. In addition to antibodies that neutralize the virus,
cytotoxic (killer) T-cells are induced by HIV infection. These cells are capable of seeking
out and killing HIV-infected cells. They, thus, form a second impediment to uncontrolled
replication of the virus, and may play an important role in slowing the rate at which HIV
causes symptoms in infected individuals. These cytotoxic T-cells are directed at the enve-
lope of HIV, but, in addition, cells with activity against other components of HIV are
present. The other components of HIV tend to vary less from strain to strain and thus are
more conserved. These observations are of importance in AIDS vaccine development in
that inclusion ofmore strictly conserved components might allow development of vac-
cines that have activity against a wider variety of strains.
Because of the relentless progress of infection in most individuals, the effectiveness of
the HIV-specific immune response that can be detected within the first several months of
infection has been called into question. Despite this consideration, it should be noted that
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individuals, once infected with one strain of virus, are rarely, if ever, infected by other
strains, even when repeated exposure to other strains occurs frequently. This suggests that
although the naturally occurring immune response might fail to prevent onset of disease
following infection, it is at least capable of preventing infection with additional strains of
virus. Thus, if an immune response that closely mimics the response following natural
infection can be elicited by an AIDS vaccine, subsequent infection with live virus might
well be preventable.
Steps in the Development of an AIDS Vaccine
As basic understanding of the HIV-specific immune response is developed, application
of this information to the technical aspects of vaccine development will be increasingly
effective. Induction of an effective immune response requires delivery of an appropriate
stimulus (termed antigen) to the immune system prior to exposure to the natural agent.
Antigen delivery may be achieved through the use of either living or nonliving material
(table 1). One of the oldest approaches to vaccines has involved growing the agent itself in
the laboratory, then purifying and killing it by chemical means. The purified, killed mate-
rial is then injected into the individual being vaccinated and, thus, is presented to the
immune response. The magnitude of the immune response is highly dependent on how a
vaccine is delivered (that is, whether it is injected or given by other routes) and on carrier
or other materials (termed adjuvants) that may be added to the killed virus. Killed virus
approaches have the advantage that they are technologically straightforward, but the dis-
advantage that most of the material injected consists of portions of the infectious agent that
are irrelevant to the immune response in developing protective immunity. Thus, the theo-
retical possibility exists that undesired vaccine side effects may be induced by the pres-
ence of unnecessary vaccine components. Finally, there is the unlikely possibility that the
inactivation procedure may be incomplete. If the vaccine preparation steps do not com-
pletely kill the virus, infection with the agent for which the vaccine is intended in the first
place could occur. In addition, there has been at least one instance in which killed vaccine
was contaminated with a virus of a different type (in the case of an early lot of polio vac-
cine) which was not killed by the inactivation procedure. Although these two latter possi-
bilities are increasingly unlikely with modern technology, they are not totally outside the
realm of possibility.
Table 1
Antigen Delivery Systems
A. Nonliving antigen delivery systems
1. Killed whole virus
2. Viral components
a. Purified from whole virus
b. Prepared by recombinant DNA technology
B. Live antigen delivery systems
1. Attenuated virus
2. Viral components carried by a nonpathogenic (or minimally pathogenic)
unrelated virus
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A second approach to vaccine preparation using nonliving material involves use of viral
components, termed subunits. These subunits can be purified from whole, killed virus,
or they can be prepared with DNA technology. This approach involves introduction of a
selected portion of the viral genetic information into the genetic material of another living
organism, such as a bacterium or a yeast. The material normally encoded by the viral
gene selected is then made by the new host. When the new host is grown in the laboratory,
large amounts of the HIV component are also produced. This material can then be puri-
fied and utilized as a vaccine. The advantage of this approach is that it has the potential to
produce well-characterized portions of the virus at great purity. By selecting a portion of
the viral genetic material which encodes for portions of the virus which appear to be tar-
gets of the protective component(s) of the immune response, one can avoid introduction of
deleterious or irrelevant viral components. Thus, one could include only selected portions
of the viral envelope or other components. Recombinant DNA technology has the disad-
vantage, however, of producing material that might be more likely to induce an immune
response that is specific only for the strain (or closely related strains) from which the
initial genetic information was procured. Recombinant DNA technology also runs the risk
of producing material that will be slightly different from the material encoded by the
native gene, owing to events that occur within cells following initial protein production.
These events relate mainly to the way in which the proteins are folded after production,
and to the addition of sugar molecules. Newer developments in molecular biology have
circumvented some, but not all, of these problems.
Live virus approaches have several potential advantages over those utilizing nonliving
material. These include the fact that vaccine delivery may be achieved without injection
(for example, through oral or aerosol routes). It has also been said that live agent ap-
proaches may be more likely to stimulate a more global immune response, both in terms
of the viral components recognized and in terms of the development of immunity at likely
sites of infection, such as mucosal surfaces. The live virus approach that is used most
frequently involves the introduction of changes (termed attenuation markers) in the nor-
mal viral genetic material which make the agent less likely to cause disease. A virus that
has been modified by addition of these attenuation markers is termed an attenuated virus.
Once the host has dealt with the attenuated virus, the immune response developed during
this interaction is capable of preventing infection with the natural (wild) virus. This ap-
proach is the one that was used in the production of the Sabin vaccine for polio.
The final potential advantage of live agent vaccines is that they might spread to unvacci-
nated contacts of the persons initially vaccinated. Thus, vaccinating one individual might
lead to the protection of others, who become secondary vaccinees. Secondary vaccination
may be good for the population, but the potential for harm exists, as well, if the attenuated
agent is introduced into individuals whose immune responses are incapable of preventing
morbidity even from the attenuated strain of virus used in the vaccination. The biggest
drawback concerning the use of attenuated viruses as vaccines relates to uncertainty as
to whether the changes introduced to include attenuation are stable. If these attenuation
markers revert to the wild state after replication begins to occur in an individual receiving
the vaccine, the deleterious effects are obvious.
An alternative to using attenuated virus involves the insertion of a portion of the viral
genetic material important for induction of immunity into an agent that does not normally
cause illness. As the agent of low pathogenicity replicates, the host immune response is
also presented with the immunologically relevant portion(s) of the agent being vaccinated
against. The resulting immune response then, in theory, prevents infection with the wild
139
New England Journal ofPublic Policy
agent if it is subsequently encountered. Although this approach shares many of the advan-
tages of the attenuated virus approach, the possibility of inadvertently introducing wild
virus is eliminated. One of the potential hazards, however, relates to concerns that while
the carrier virus chosen might be unable to cause disease in individuals with intact im-
mune responses, it might be capable of causing severe disease in individuals with immune
dysfunction. In the case of the most intensively studied carrier virus (vaccinia), such con-
cerns would exist in vaccination plans in which individuals who were already HIV-in-
fected might be inadvertently vaccinated. This concern would include either direct or
secondary vaccination, as discussed above.
Current Status ofHIV Vaccine Research
At the time of this writing (March 1988), a large number of academic and industrial inves-
tigators have focused attention on AIDS vaccine research and production. Most of the
scientific attention has centered on approaches that utilize the viral envelope or portions
of the envelope as the primary component of candidate vaccines. Live and killed virus
approaches have succeeded in producing immunogenes (vaccines) that induce neutralizing
antibodies in laboratory animals ranging from mice to nonhuman primates. To date, most,
if not all, of the animals vaccinated have produced antibodies that will neutralize only the
strain or type of the virus from which the candidate vaccine was derived. Thus, attempts
to produce a vaccine that might offer broad protection against a wide variety of strains or
types have been unsuccessful. Vaccines useful in the United States may have limited utility
in parts of the world where other viral strains are prevalent.
Only a handful of studies have progressed to the point that chimpanzees have been vac-
cinated with a candidate vaccine and then have been challenged with live virus. Most of
these studies have not yet been reported in peer-reviewed scientific literature. In these
studies, in general, although neutralizing antibodies have been elicited by the candidate
vaccines, animals subsequently inoculated with live virus, even of the vaccine strains,
have become infected. This failure to prevent infection might stem from any one of a
number of factors. These include the inadequacy of the candidate vaccine and the proba-
bility that the live virus inoculation studies have used an excess amount of virus. In the
chimpanzee challenge studies performed to date, most animals are challenged intrave-
nously with many thousands of infectious virions. In human infection, it is clear that most
sexual exposures do not result in transmission of virus. Those exposures which result in
infection may do so because slightly more virus is present, or because of defects in the
rectal or vaginal surfaces. Thus, in order for the chimpanzee challenges to accurately
reflect human infection, it would be necessary to develop a model whereby animals were
inoculated with much smaller amounts of virus, preferably administered to mucosal sur-
faces. In such inoculations, most animals would not become infected. In order to demon-
strate protection, it would be necessary to vaccinate a large number of chimpanzees, and
to then inoculate them with a small enough amount of virus that most of them would not
become infected, even if unvaccinated. In such a study, one might immunize 100 animals
with a test vaccine and another 100 with a sham (or fake) vaccine. One would then inocu-
late each animal with an amount of virus just in excess of what might infect a minority of
unvaccinated animals. At the end of a study like this, a successful vaccine might reduce
the number of infected animals from 8 of the 100 in the sham-vaccinated group to 2 of the
100 in the group receiving the active vaccine. Such studies would require tens to hundreds
of chimpanzees per vaccine candidate. Given the short supply of chimpanzees, and the
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cost of each animal (currently approximately $70,000), it is unlikely that such studies are
feasible.
Thus, at this point, a number of vaccine candidates have been developed. Many produce
neutralizing antibodies in vaccinated animals. None has yet been demonstrated to protect
animals from live virus challenge. Even if a vaccine demonstrated protection from infec-
tion in the chimpanzee model, it would not necessarily imply protection of humans in the
real world setting. Therefore, even with all the knowledge theoretically available from
animal studies, human vaccine studies will be required prior to licensure of an AIDS
vaccine.
Human Studies with Candidate AIDS Vaccines
The human studies that must be undertaken in the evaluation process for AIDS vaccines
will be patterned after such studies with other vaccines in the past. A logical sequence of
studies progressing from simple dose-finding studies to larger-scale clinical trials will
assure the most timely evolution ofAIDS vaccine and will minimize the inherent risks to
study subjects which are encountered with evaluation of any vaccine or drug product.
The process that is generally followed involves Phase I studies, in which the candidate
vaccine is administered to a small group of healthy human volunteers who are at minimal
risk for acquiring the agent being vaccinated against. In these studies, the primary goal is
to determine whether any toxicities not anticipated from animal studies might be manifest
in human subjects. In addition, through the use of several laboratory assays, these studies
seek to measure the magnitude of the immune response induced by the vaccine. This en-
deavor will not necessarily identify adverse effects that might occur at a low frequency or
that might occur in populations not included in the preliminary testing. The immunologic
changes that are measured will be useful only in that they will indicate whether the immu-
nologic impact of the vaccine in humans is similar to that experienced by animals in the
prior studies.
The Phase I studies might involve several different vaccination schedules or doses of
vaccine, and might compare the magnitude of the response encountered when the vaccine
is given with various adjuvants (immune-enhancing materials). In some vaccine develop-
ment programs, the Phase I studies are performed in several stages, in which adverse
and immunologic effects are measured in a very small group of volunteers (five to ten
persons) before they are repeated or modified for application to a larger number of
volunteers.
After Phase I testing has been completed, information should be in hand about optimal
dosing schedules and adverse effects of a vaccine. The next phase of the studies focuses on
whether a vaccine actually prevents infection in the field. In such studies, members of a
group or groups at risk for acquiring the agent are recruited and invited to participate in a
placebo-controlled trial. In these studies, subjects are randomly allotted to one of two or
three groups who will either receive the vaccine candidate or an identical-appearing pla-
cebo. Subjects are allotted by chance to these groups; neither the subject nor the investiga-
tor knows who receives the theoretically active material. Subjects are then followed to
determine whether the group or groups receiving the vaccine are infected at a lower rate
over time than those who receive the placebo. Only after such evidence is in hand is a
vaccine considered safe and effective and is it offered for general use. Such information is
mandatory, because premature licensure and use of an ineffective vaccine would give the
public a false sense of security and would encourage behavior that would increase the rate
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of infection. In general, most effective vaccines offer a significant degree of protection,
but not complete protection. The speed with which a trial can demonstrate the effective-
ness of a vaccine is directly related to the rate at which the study population acquires the
agent being studied, and to the proportion of vaccinated individuals who are protected
from infection by virtue of being vaccinated.
Although the need for such studies seems self-evident, in the case of AIDS vaccine
studies practical and ethical concerns will make them extremely difficult to design. In the
initial studies, it will be critically important to be certain that individuals who are already
infected with HIV, or who are likely to become so in the ensuing several months, are
excluded. This is important, since one would not wish to put a potentially useful vaccine at
risk of being prematurely discarded because clinical manifestations of HIV infection are
mistaken for untoward effects of the vaccine. In most vaccine studies in the past, these
concerns have caused investigators to move totally out of "at risk" groups for the very
early studies. Politically, this might prove to be difficult with respect to an AIDS vaccine,
since individuals at risk for HIV infection have expressed a strong desire to be an integral
part of any vaccine studies, from even the earliest phase through the finish. This consider-
ation has caused some investigators to consider offering enrollment to HIV-seronegative
homosexual men who have been abstinent for three months and who will guarantee absti-
nence during the period of the vaccine trial.
In the placebo-controlled trial, in which participants will be at risk of HIV infection,
other ethical considerations are operative. Subjects must understand the study design in
terms of the placebo inclusion. They must be told that even if they receive active material,
the vaccine may not work. Finally, participants must be counseled about modes of infec-
tion and must be advised not to put themselves at risk of infection. To the extent that the
counseling is effective, it will be increasingly difficult to demonstrate a protective effect
of the vaccine. This is related to the fact that in order for a vaccine to demonstrate protec-
tion from infection, vaccine recipients and control subjects need to have a significant
exposure rate. If trial members receive vaccine or placebo, and then are never exposed to
the virus, it will not be possible to determine whether the vaccine is protective. An addi-
tional consideration relates to the need to protect the confidentiality of study subjects.
This extends beyond usual concerns for such studies, because vaccinees will likely be
designated HIV-seropositive by the standard HIV serologic screening tests. To the extent
that widespread mandatory testing is employed or appears to be on the horizon, potential
vaccine study participants will have a strong disincentive to take part in such vitally im-
portant trials. It has been proposed that vaccine trial participants be given certificates
indicating participation in HIV vaccine trials in order to indemnify them from retribution
from insurance companies and others. These certificates might or might not be useful to
Table 2
Attributes of an Ideal AIDS Vaccine
1
.
Effective against a wide variety of HIV strains and types
2. Lacking immune-pathogenic or other untoward effects
3. Effective against genital, blood-borne, or percutaneous exposure
4. Inexpensive to prepare
5. Easy to administer
6. Stable upon storage
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participants, and would certainly expose them to a loss of confidentiality in terms of risk
group behavior if they were utilized.
A final consideration relates to the fact that successful completion of placebo-con-
trolled vaccine studies in one risk group will not assure protection to persons in other risk
groups. In the case of sexual exposure, it is likely that less virus is presented than with
intravenous exposure with intravenous drug use and in transfusion-associated HIV trans-
mission. In addition, in that intravenous drug users and hemophiliacs not infected by HIV
are frequently immunosuppressed by drugs and clotting factors, respectively, the immu-
nologic response to a candidate vaccine might be less vigorous than that in healthy homo-
sexual men. Thus, it will be necessary to carry out vaccine trials in several different
risk group populations (for example, homosexual men, intravenous drug users, heterosex-
uals, and hemophiliacs).
The Ideal Vaccine
The ideal AIDS vaccine must satisfy several requirements (table 2). Development of such
a vaccine requires a thorough understanding of the modes of transmission of HIV, of the
mechanisms by which the virus causes illness and death, and of strain variability among
HIV isolates. The ideal vaccine must be safe; effective against a variety of HIV isolates;
protective against either sexual or blood-borne exposure through needle sticks; inexpen-
sive to produce; easy to administer; and stable in storage for prolonged periods. Techno-
logical progress in basic vaccine design over the past decade makes it likely that such a
vaccine will ultimately be produced. However, the impediments to development of such a
vaccine are substantial and are unlikely to be overcome in the near future. Although any
timetable must be viewed as highly speculative, a possible one is presented in table 3. The
vaccine development process is already well under way, having begun with the initial
description of the syndrome in 1981 . As outlined in the table, vaccine development should
be viewed as an orderly process that consists of a series of temporally overlapping but
discrete phases. At the present time, limited dose-finding studies have begun. These stud-
ies seek to determine whether vaccine preparations are safe to administer, and what dos-
ing schedule induces the most potent immune response. Once an optimal dosing regimen
has been established, larger, more elaborate trials will be required to determine whether
the vaccine or vaccines actually prevent infection. Following this demonstration in several
risk groups, the vaccine will be made available for commercial production. Although it is
extremely difficult to make such predictions with precision, it seems unlikely to this au-
thor that AIDS vaccines will be widely available until at least 1994 or 1995.
Table 3
Timetable, Past and Potential, in the Development of an AIDS Vaccine
1981 Clinical recognition of acquired immunodeficiency syndrome
1983-84 Identification of HIV as etiologic agent for AIDS
1984-87 Delineation of components of HIV recognized by host immune response
1987-88 Phase I human studies (safety and dose finding)
1989-93 Phase II and Phase III human studies (controlled larger-scale clinical trials
with vaccine candidates)
1994-95 AIDS vaccine licensure
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Conclusion
In summary, much is now known about the immune response to HIV. This basic knowl-
edge has formed the framework for initial plans for developing AIDS vaccines. AIDS
vaccine studies have progressed to the point that portions of the virus have been identified
which are capable of generating neutralizing activity in animals. To date, however, no
vaccine preparation has been shown to prevent infection with live HIV following a chal-
lenge with the pathogenic virus. Human studies are in the earliest phase at this writing,
but are both technically and ethically highly complex. It is likely that a vaccine or vaccines
that offer a degree of protection, if not full protection, will be developed. It is the opinion
of this investigator that such a development is at least five years away. V|)
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